Appendix A: Key to Acronyms
Study and Trial Names
| Acronym/Abbreviation | Name |
|---|---|
| ACTG | AIDS Clinical Trials Group |
| ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
| ARDENT | ACTG A5257 trial |
| ARTEMIS | Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| CARES | Cabotegravir and Rilpivirine Efficacy and Safety |
| CoRECT | Cooperative Re-Engagement Controlled Trial |
| D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
| D2EFT | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy |
| ECHO | Evidence for Contraceptive Options in HIV |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| HPTN | HIV Prevention Trials Network |
| LATITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
| REPRIEVE | Randomized Trial to Prevent Vascular Events in HIV |
| STaR | Single-Tablet Regimen |
| START | Strategic Timing of AntiRetroviral Treatment |
| THRIVE | Targeting HIV Retention and Improved Viral Load Through Engagement |
| VACS | Veterans Aging Cohort Study |
| WIHS | Women’s Interagency HIV Study |
Appendix A: Key to Acronyms
Study and Trial Names
| Acronym/Abbreviation | Name |
|---|---|
| ACTG | AIDS Clinical Trials Group |
| ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
| ARDENT | ACTG A5257 trial |
| ARTEMIS | Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| CARES | Cabotegravir and Rilpivirine Efficacy and Safety |
| CoRECT | Cooperative Re-Engagement Controlled Trial |
| D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
| D2EFT | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy |
| ECHO | Evidence for Contraceptive Options in HIV |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| HPTN | HIV Prevention Trials Network |
| LATITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
| REPRIEVE | Randomized Trial to Prevent Vascular Events in HIV |
| STaR | Single-Tablet Regimen |
| START | Strategic Timing of AntiRetroviral Treatment |
| THRIVE | Targeting HIV Retention and Improved Viral Load Through Engagement |
| VACS | Veterans Aging Cohort Study |
| WIHS | Women’s Interagency HIV Study |
Download Guidelines
- Section Only PDF (88.31 KB)
- Full Guideline PDF (5.5 MB)
- Recommendations Only PDF (239.25 KB)
- Tables Only PDF (2.19 MB)